Ultra-Low-Priced Lithium Stock Offers Unlimited Upside in Global EV Boom
Lithium batteries are supplying our planet with clean reliable energy. EVs, laptops, cell phones...you name it. The Smart Money is going into the future suppliers of lithium like this US$0.15 stock that just secured a game-changing lithium asset.
Details Here.
pixel

SCLP Insider Trading (Scancell)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £240,000
Insider Selling (Last 12 Months): £152,000

Scancell Insider Trading History Chart

Scancell Share Price & Price History

GBX 21.60
▲ +0.1 (0.47%)
As of 06/14/2021 01:00 AM ET
Days: 30 | 90 | 365
Profit-Alert: Follow the Smart Money in the Global EV Boom
The Electric Vehicle boom is here! This upstart lithium developer is positioning to be a future supplier to Tesla’s Gigafactory in the Nevada desert. Best of all, it’s currently undiscovered by Wall Street below US$1 per share.
Click here for details...
pixel

Scancell Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/4/2021Martin DiggleInsiderBuy350,000GBX 19£66,500
4/29/2021Martin DiggleInsiderBuy400,000GBX 20£80,000
2/18/2021Martin DiggleInsiderSell200,000GBX 28£56,000
2/16/2021Martin DiggleInsiderSell400,000GBX 24£96,000
12/14/2020Martin DiggleInsiderBuy750,000GBX 11£82,500
11/24/2020Cliff HollowayInsiderBuy100,000GBX 11£11,000
4/27/2020Martin DiggleInsiderSell1,500,000GBX 8£120,000
12/16/2019Martin DiggleInsiderBuy2,925,000GBX 5£146,250
See Full Table
Scancell logo
Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 that is in phase I/II combination trials for the treatment of non-small cell lung cancer; and Modi-1, which is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2 that is in pre-clinical trial for the treatment of multiple solid tumors. The company has a research collaboration agreement with BioNTech to develop T-cell receptor based therapeutics; licensing and collaboration agreement with ISA Pharmaceuticals B.V. to use ISA's AMPLIVANT adjuvant technology for the development and commercialization of Modi-1; and collaboration agreements with Cobra Biologics, Centre for Research on Global Virus Infections, the University of Nottingham, and the Nottingham Trent University to develop a vaccine for COVID-19. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
Read More on Scancell

Today's Range

Now: GBX 21.60
21
22

50 Day Range

MA: GBX 21.62
19
24

52 Week Range

Now: GBX 21.60
5.07
29

Volume

566,784 shs

Average Volume

2,092,647 shs

Market Capitalization

£176.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Scancell?

Scancell's top insider shareholders include:
  1. Cliff Holloway (Insider)
  2. Martin Diggle (Insider)
Ultra-Low-Priced Lithium Stock Offers Unlimited Upside in Global EV Boom
Lithium batteries are supplying our planet with clean reliable energy. EVs, laptops, cell phones...you name it. The Smart Money is going into the future suppliers of lithium like this US$0.15 stock that just secured a game-changing lithium asset.
Details Here.
pixel